Allergy Therapeutics plc (LON:AGY) said it has signed a contract with Germany’s AGC Biologics to scale up the manufacturing of its Polyvac Peanut product for use in clinical studies.
The vaccine is being developed to guard against anaphylaxis and it is hoped it will also induce protective immunity.
READ: Allergy Therapeutics' grass pollen study running ahead of schedule
Chief executive Manuel Llobet said: "The disruption to patients' social and family life as a result of food allergies is significant, and we are committed to addressing these current unmet needs.
“The group's peanut vaccine programme complements our current marketed range of ultra-short course vaccines in terms of safety, efficacy and improved patient convenience.
“We are pleased to start working with AGC Biologics in order to further progress the clinical programme."